{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:51:47Z","timestamp":1791971507710,"version":"4.3.4"},"reference-count":44,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>There are currently no oral treatment options for infections caused by extended spectrum \u03b2\u2011lactamase\u2010producing Enterobacterales. Avibactam tomilopil, a novel oral prodrug of avibactam, is being developed in combination with the oral cephalosporin, ceftibuten, as a potential treatment for patients with complicated urinary tract infections (cUTIs). The safety, tolerability, and pharmacokinetic profiles of single and multiple doses of avibactam tomilopil (900 to 1350 mg) and ceftibuten (400 to 1600 mg), alone and\/or in combination were evaluated in three Phase 1 trials in healthy participants. Avibactam tomilopil was rapidly metabolized to active avibactam and plasma avibactam exposure increased proportionately with dose. Both avibactam and cis\u2010ceftibuten had similar plasma half\u2010lives, and were predominantly renally excreted. While there was negligible food effect on ceftibuten exposures, plasma avibactam exposure in the fed state for a fixed\u2010dose combination ceftibuten\u2010avibactam tomilopil tablet was higher compared with the fasted state. Based on joint probability of target attainment simulations using a simultaneous oral ceftibuten\u2011avibactam tomilopil population pharmacokinetic model, a tablet formulation ceftibuten 400 mg + avibactam tomilopil 1200 mg dosed every 8 h without regard to food is proposed for Phase 3 evaluation in adult patients with cUTIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>Trial registration: NCT03931876; NCT05554237; NCT06593054.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jcph.70263","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:42:23Z","timestamp":1788273743000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose Selection for Ceftibuten Combined with Avibactam Tomilopil, a Potential Oral Alternative to Carbapenems for Patients with Complicated Urinary Tract Infections"],"prefix":"10.1002","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-3427","authenticated-orcid":false,"given":"Siddhee A.","family":"Sahasrabudhe","sequence":"first","affiliation":[{"name":"Pfizer Inc.  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0222-1055","authenticated-orcid":false,"given":"Satoshi","family":"Shoji","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D  Japan Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2196-5782","authenticated-orcid":false,"given":"Abhijeet S.","family":"Jakate","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9834-8442","authenticated-orcid":false,"given":"Bisrat K.","family":"Abraham","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima S.","family":"Toussi","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Pearl River NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Maligalig","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Makati City Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda S.","family":"Darekar","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D UK Ltd.  Tadworth Surrey UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5151-9983","authenticated-orcid":false,"given":"Sakambari","family":"Tripathy","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantino","family":"Kantaridis","sequence":"additional","affiliation":[{"name":"Pfizer CRU  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3058-1996","authenticated-orcid":false,"given":"Josue K.","family":"Mfopou","sequence":"additional","affiliation":[{"name":"Pfizer CRU  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oxana","family":"Selivanova","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Pearl River NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Bergman","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4455-5780","authenticated-orcid":false,"given":"Negar Niki","family":"Alami","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Pearl River NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6298-8219","authenticated-orcid":false,"given":"Ravi Shankar P.","family":"Singh","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:82532"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2217951"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaa111"},{"key":"e_1_2_11_5_1","unstructured":"Centers for Disease Control and Prevention.Covid\u201019: U.S. impact on antimicrobial resistance special report 2022. Atlanta GA: U.S. Department of Health and Human Services.2022.https:\/\/stacks.cdc.gov\/view\/cdc\/119025\/cdc_119025_DS1.pdf"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914433"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab092"},{"key":"e_1_2_11_8_1","doi-asserted-by":"crossref","unstructured":"BushK BradfordPA.Epidemiology of \u03b2\u2010lactamase\u2010producing pathogens.Clin Microbiol Rev.2020;33(2):e00047\u201000019.","DOI":"10.1128\/CMR.00047-19"},{"key":"e_1_2_11_9_1","unstructured":"World Health Organization.WHO bacterial priority pathogens list 2024: bacterial pathogens of public health importance to guide research development and strategies to prevent and control antimicrobial resistance.2024. Accessed January 2 2026.https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/1a41ef7e\u2010dd24\u20104ce6\u2010a9a6\u20101573562e7f37\/content"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01867-1"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab560"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2022.04.003"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07167-y"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.11.025"},{"key":"e_1_2_11_16_1","volume-title":"2023 Antibacterial agents in clinical and preclinical development: an overview and analysis","author":"World Health Organization","year":"2024"},{"key":"e_1_2_11_17_1","unstructured":"Pernix Therapeutics LLC.Cedax\u00ae (ceftibuten capsules) and (ceftibuten for oral suspension).2010. Accessed June 24 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/050686s016lbl.pdf"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02446-17"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04191-14"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv132"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00499-7"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad280"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.2.356"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.2.359"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199528050-00003"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03609-x"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12585"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01346-22"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae452"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-023-04562-4"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2005.04.005"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.11.003"},{"key":"e_1_2_11_33_1","unstructured":"R Core Team.R: a language and environment for statistical computing.2022.https:\/\/www.R\u2010project.org\/"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.11.2267"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.793"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.3733\/hilg.v06n11p315"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199630050-00001"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23574"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.24.25"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02187-18"},{"key":"e_1_2_11_43_1","unstructured":"XieR ChanPLS McFadyenLM RaberS.Abstract 990: Development of a simultaneous population pharmacokinetic model for aztreonam\u2010avibactam. 30th European Congress of Clinical Microbiology and Infectious Diseases 2020;Paris France.https:\/\/www.escmid.org\/fileadmin\/escmid\/media\/pdf\/escmid_global_replays\/ECCMID2020abstractbook.pdf"},{"key":"e_1_2_11_44_1","unstructured":"Center for Drug Evaluation and Research.Application number: 206494orig1s000. Ceftazidime\u2010avibactam. Clinical pharmacology and biopharmaceutics review(s).2015. Accessed June 24 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/206494orig1s000cllinpharmr.pdf"},{"key":"e_1_2_11_45_1","unstructured":"Pfizer.Summary of product characteristics: Zavicefta 2 g\/0.5 g powder for concentrate for solution for infusion.2024. Accessed August 18 2025.https:\/\/www.ema.europa.eu\/documents\/product\u2010information\/zavicefta\u2010epar\u2010product\u2010information_en.pdf"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70263","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.70263","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:20:22Z","timestamp":1791969622000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.70263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/jcph.70263"],"URL":"https:\/\/doi.org\/10.1002\/jcph.70263","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2025-12-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70263"}}